Download PDF
Thromb Haemost 1993; 70(06): 1009-1013
DOI: 10.1055/s-0038-1649716
Original Article
Fibrinolysis
Schattauer GmbH Stuttgart

The Effects of Insulin-Like Growth Factor-1 on Plasminogen Activator Inhibitor-1 Synthesis and Secretion: Results from In Vitro and In Vivo Studies

S J Padayatty
1   The Department of Endocrinology, The General Infirmary at Leeds, UK
,
S Orme
1   The Department of Endocrinology, The General Infirmary at Leeds, UK
,
P D Zenobi
2   The Division of Endocrinology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
,
M H Stickland
The Academic Unit of Medicine, The General Infirmary at Leeds, UK
,
P E Belchetz
1   The Department of Endocrinology, The General Infirmary at Leeds, UK
,
P J Grant
The Academic Unit of Medicine, The General Infirmary at Leeds, UK
› Author Affiliations
Further Information

Publication History

Received 04 May 1993

Accepted after revision 17 August 1993

Publication Date:
06 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In vitro studies have shown that insulin and IGF-1 releases the fibrinolytic inhibitor plasminogen activator inhibitor-1 (PAI-1) from cells of hepatic origin. To investigate the effects of IGF-1 on fibrinolysis: 1) cultured hepatoma cells were grown in the presence of IGF-1 and media collected for secreted PAI-1 and cells probed for PAI-1 mRNA, 2) 8 hypopituitary patients were treated with recombinant human growth hormone (rhGH) and 3) 5 type 2 diabetic patients were treated with recombinant human IGF-1 (rhIGF-1). Treatment of Hep G2 cells with IGF-1 (1000 ng/ml) increased secretion of PAI-1 from a median value of 80 ng/106 cells (range 21-91) to 144 ng/106 cells (range 128-169) after 24 h (p <0.01). Synthesis of PAI-1 mRNA increased in a similar fashion. Treatment of hypopituitary patients with rhGH led to an increase in circulating IGF-1 from a mean value of 166 (range 41-324) ng/ml at baseline to 322 (77-575) ng/ml at 4 weeks and 259 (104-533) ng/ml after 8 weeks (p <0.02). Despite this, no changes in circulating PAI-1 or fibrinolysis occurred. Type II diabetic patients treated with rhIGF-1 showed an increase in circulating IGF-1 from a mean value of 120 ng/ml (range 109-196), at baseline to 823 ng/ml (585-894) after 5 days. This also was not associated with changes in circulating PAI-1 or in fibrinolysis. The results confirm that IGF-1 induces the synthesis of PAI-1 in Hep G2 cells. However, marked increases in IGF-1 had no effect on circulating PAI-1 or fibrinolysis.

 

  • References

  • 1 Rosen T, Bengtsson B-A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
    CrossrefPubMedGoogle Scholar
  • 2 Salmon F, Cuneo RC, Hesp R, Sonksen P. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989; 321: 1797-1803
    CrossrefPubMedGoogle Scholar
  • 3 Jorgensen JDL, Thuesen L, Ingemann-Hansen T. et al. Beneficial effects of growth hormone treatment in GH deficient adults. Lancet 1989; i: 1221-1224
    PubMedGoogle Scholar
  • 4 Rudman D, Feller AG, Nagraj HJ. et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6
    CrossrefPubMedGoogle Scholar
  • 5 Hamsten A, Wiman B, deFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 6 Hamsten A, Defaire U, Waldius G, Dahlen G, Szamosi A, Landou C. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; ii: 3-9
    PubMedGoogle Scholar
  • 7 Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1 :Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989; 62: 723-728
    PubMedGoogle Scholar
  • 8 Grant PJ, Ruegg M, Medcalf RL. Basal expression and insulin mediated induction of PAI-1 mRNA in Hep G2 cells. Fibrinolysis 1991; 5: 81-86
    PubMedGoogle Scholar
  • 9 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Ailaud MF. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metabol 1987; 13: 331-336
    PubMedGoogle Scholar
  • 10 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients. Relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-373
    PubMedGoogle Scholar
  • 11 Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease. Results from two population studies in Finland. Diabetes Care 1979; 2: 131-141
    CrossrefPubMedGoogle Scholar
  • 12 Welbom TA, Weane K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160
    CrossrefPubMedGoogle Scholar
  • 13 Papoz L, Richard JL, Claude JR, Rosseling G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210
    CrossrefPubMedGoogle Scholar
  • 14 Froesch ER, Zapf J. Insulin-like growth factors and insulin: compara tive aspects. Diabetologia 1985; 28: 485-493
    CrossrefPubMedGoogle Scholar
  • 15 Holly JMP, Wass JAH. Insulin-like growth factors; autocrine, para crine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments. J Endocrinol 1989; 122: 611-618
    CrossrefPubMedGoogle Scholar
  • 16 Giacca A, Gupta R, Efendic S, Hall K, Skottner A, Lickley L. et al. Differential effects of IGF-1 and insulin on glucoregulation and fat metabolism in depancreatized dogs. Diabetes 1990; 39: 340-347
    CrossrefPubMedGoogle Scholar
  • 17 Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type 1 : Implications for vascular disease in hyperinsulinaemic states. Proc Natl Acad Sci 1991; 88: 9959-9963
    CrossrefPubMedGoogle Scholar
  • 18 Wright AD, Hill DM, Lowy C, Russell FraserT. Mortality in acromegaly. Q J Med 1970; NS 39 153: 01-16
    PubMedGoogle Scholar
  • 19 Medcalf RL, van den Berg EA, Schleuning W-D. Glucocorticoid modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 1988; 106: 971-978
    CrossrefPubMedGoogle Scholar
  • 20 Minty A-J, Alonso S, Guenet J-L, Buckingham M-E. Number and organization of acting related sequences in the mouse genome. J Mol Biol 1983; 167: 77-81
    CrossrefPubMedGoogle Scholar
  • 21 Orme SM, Sebastian JR, Oldroyd B. et al. Comparison of measures of body composition in a trial of low-dose growth hormone replacement therapy. Clin Endocrinol 1992; 37: 453-459
    CrossrefPubMedGoogle Scholar
  • 22 Zenobi PD, Jaeggi-Groisman SE, Riesen W, Rder ME, Froesch ER. Insulin-like growth factor-1 improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992; 90: 2234-2241
    CrossrefPubMedGoogle Scholar
  • 23 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 24 Nilsson IM, Hedner U, Pandolfi M. The measurement of fibrinolytic activities. In: Fibrinolytes and Antifibrinolytes. Markward F. ed. Berlin: Springer; 1978: 107-134
    Google Scholar
  • 25 Furlanetto RW, Underwood LE, Van WyckJJ, D’Ercole J. Estima tion of somatomedin C levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977; 60: 648-657
    CrossrefPubMedGoogle Scholar
  • 26 Bristow AF, Gooding RP, Gaines Das RE. The International reference reagent for insulin-like growth factor-1. J Endocrinol 1990; 125: 191-197
    CrossrefPubMedGoogle Scholar
  • 27 Zenobi PD, Graf S, Ursorung H, Froesch ER. Effects of insulin-like growth factor-1 on glucose tolerance, insulin levels and insulin secretion. J Clin Invest 1992; 89: 1908-1913
    CrossrefPubMedGoogle Scholar
  • 28 Stout RW, Vallance-Owen J. Insulin and atheroma. Lancet 1971; i: 1078
    PubMedGoogle Scholar
  • 29 Jarret RJ. Is insulin atherogenic?. Diabetologia 1988; 31: 20
    PubMedGoogle Scholar
  • 30 Duff GL, McMillan GC. The effect of alloxan diabetes on experimental atherosclerosis in the rabbit. I. The inhibition of experimental atherosclerosis in alloxan diabetes. II. The effect of alloxan diabetes on the regression of experimental cholesterol atherosclerosis J Exp Med 1949; 89: 611-630
    CrossrefPubMedGoogle Scholar
  • 31 Marquie G. Effect of insulin in the induction and regression of experimental cholesterol atherosclerosis in the rabbit. Postgrad Med J 1978; 54: 80-85
    CrossrefPubMedGoogle Scholar
  • 32 Grant PJ, Kruithof EKO, Felley CP, Felber JP. Bachmann F. Short term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-516
    CrossrefPubMedGoogle Scholar
  • 33 Potter van Loon BJ, de Bart ACW, Radder JK, Frolich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 4 (Suppl. 02) 93-94
    PubMedGoogle Scholar
  • 34 Landin K, Tengborn L, Chmielewska J, von SchenckH, Smith U. The acute effect on insulin on tissue plasminogen activator and plasmino gen activator inhibitor in man. Thromb Haemostas 1991; 65: 130-133
    PubMedGoogle Scholar
  • 35 Bornfeldt KE, Gidlöf RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. Binding and biological effects of insulin, insulin analo gues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307-313
    CrossrefPubMedGoogle Scholar
  • 36 Salamon EA, Luo J, Murphy LJ. The effect of acute and chronic insulin administration on insulin-like growth factor-1 expression in the pituitary intact and hypophysectomised rat. Diabetologia 1989; 32: 348-354
    CrossrefPubMedGoogle Scholar
  • 37 Caro JF, Poulos J, Hoop O, Pories WJ, Flichinger EG, Sinha MK. Insulin-like growth factor 1 binding in hepatocytes from human liver, human hepatoma, and normal regenerating, and fetal liver. J Clin Invest 1988; 81: 976-981
    CrossrefPubMedGoogle Scholar
  • 38 Foss MC, Sead MJA, Paccola MGF, Paula FJA, Piccinato CE, Moreira AC. Peripheral glucose metabolism in acromegaly. J Clin Endocrinol Metab 1991; 72: 1048-1053
    CrossrefPubMedGoogle Scholar
  • 39 Binnerts A, Deurenberg P, Swart GR, Wilson JHP, Lamberts WJ. Body composition in growth hormone deficient adults. Am J Clin Nutr 1992; 55: 918-923
    CrossrefPubMedGoogle Scholar